John Pickup

List of Publications by Year in descending order

56 papers	7,888 citations	136950 32 h-index	161849 54 g-index
59 all docs	59 docs citations	59 times ranked	7349 citing authors

#	Article	IF	Citations
1	Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes. Diabetes Care, 2004, 27, 813-823.	8.6	1,171
2	NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia, 1997, 40, 1286-1292.	6.3	1,108
3	Is Type II diabetes mellitus a disease of the innate immune system?. Diabetologia, 1998, 41, 1241-1248.	6.3	892
4	Severe hypoglycaemia and glycaemic control in TypeÂ1 diabetes: metaâ€analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabetic Medicine, 2008, 25, 765-774.	2.3	550
5	Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.. BMJ: British Medical Journal, 1978, 1, 204-207.	2.3	493
6	Plasma interleukin-6, tumour necrosis factor Î± and blood cytokine production in type 2 diabetes. Life Sciences, 2000, 67, 291-300.	4.3	476
7	Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ: British Medical Journal, 2011, 343, d3805-d3805.	2.3	442
8	Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ: British Medical Journal, 2002, 324, 705-705.	2.3	413
9	Continuous Subcutaneous Insulin Infusion at 25 Years: Evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care, 2002, 25, 593-598.	8.6	362
10	Real-Time Continuous Glucose Monitoring in Type 1 Diabetes: A Qualitative Framework Analysis of Patient Narratives. Diabetes Care, 2015, 38, 544-550.	8.6	145
11	Real-Time Continuous Glucose Monitoring Significantly Reduces Severe Hypoglycemia in Hypoglycemia-Unaware Patients With Type 1 Diabetes. Diabetes Care, 2013, 36, 4160-4162.	8.6	139
12	Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in Type 1 diabetic subjects. Diabetic Medicine, 2003, 20, 1012-1015.	2.3	123
13	continuous Subcutaneous Insulin Infusion in the Treatment of Diabetes Mellitus. Diabetes Care, 1980, 3, 290-300.	8.6	118
14	LONG-TERM CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN DIABETICS AT HOME. Lancet, The, 1979, 314, 870-873.	13.7	117
15	In vivo molecular sensing in diabetes mellitus: an implantable glucose sensor with direct electron transfer. Diabetologia, 1989, 32, 213-217.	6.3	105
16	Long-Acting Insulin Analogs Versus Insulin Pump Therapy for the Treatment of Type 1 and Type 2 Diabetes. Diabetes Care, 2008, 31, S140-S145.	8.6	93
17	Innate immunity, insulin resistance and type 2 diabetes. Diabetologia, 2012, 55, 273-278.	6.3	92
18	Serum sialic acid and acute phase proteins in type 1 and type 2 diabetes mellitus. Clinica Chimica Acta, 1993, 219, 131-138.	1.1	72

#	Article	IF	Citations
19	Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. Diabetes Care, 2017, 40, 715-722.	8.6	70
20	Frequency of diabetic ketoacidosis and hypoglycemic coma during treatment with continuous subcutaneous insulin infusion. Audit of medical care. American Journal of Medicine, 1985, 79, 685-691.	1.5	67
21	Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption.. BMJ: British Medical Journal, 1981, 282, 347-350.	2.3	66
22	Costâ€effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in TypeÂ1 diabetes: a systematic review. Diabetic Medicine, 2015, 32, 1415-1424.	2.3	58
23	Is insulin pump therapy effective in Type 1 diabetes?. Diabetic Medicine, 2019, 36, 269-278.	2.3	54
24	Serum Sialic Acid Concentration and Coronary Heart Disease in NIDDM. Diabetes Care, 1995, 18, 1100-1103.	8.6	53
25	In Vivo Glucose Monitoring: Sense and Sensorbility. Diabetes Care, 1993, 16, 535-539.	8.6	48
26	Safety of continuous subcutaneous insulin infusion: Metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion. Diabetologia, 1982, 22, 175-9.	6.3	44
27	Activation of the innate immune system as a predictor of cardiovascular mortality in Type 2 diabetes mellitus. Diabetic Medicine, 2003, 20, 723-726.	2.3	43
28	Clinicians' requirements for chemical sensors for in vivo monitoring: A multinational survey. Biosensors and Bioelectronics, 1991, 6, 639-646.	10.1	42
29	Responses and calibration of amperometric glucose sensors implanted in the subcutaneous tissue of man. Acta Diabetologica, 1993, 30, 143-148.	2.5	40
30	The innate immune response and type 2 diabetes: evidence that leptin is associated with a stress-related (acute-phase) reaction. Clinical Endocrinology, 2000, 52, 107-112.	2.4	36
31	Point: Are Insulin Pumps Underutilized in Type 1 Diabetes? Yes. Diabetes Care, 2006, 29, 1449-1452.	8.6	33
32	NICE guidance on continuous subcutaneous insulin infusion 2008: review of the technology appraisal guidance. Diabetic Medicine, 2009, 26, 1-4.	2.3	33
33	Variations in the quality and sustainability of longâ€term glycaemic control with continuous subcutaneous insulin infusion. Diabetic Medicine, 2014, 31, 1174-1177.	2.3	30
34	Plasma sialic acid in animal models of diabetes mellitus: Evidence for modulation of sialic acid concentrations by insulin deficiency. Life Sciences, 1995, 57, 1383-1391.	4.3	27
35	Implantable glucose sensors: Choosing the appropriate sensing strategy. Biosensors, 1987, 3, 335-346.	1.7	25
36	Continuous subcutaneous insulin infusion in type 1 diabetes. BMJ: British Medical Journal, 2001, 322, 1262-1263.	2.3	25

#	Article	IF	Citations
37	Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB Prospective Complications Study (PCS). Diabetologia, 2008, 51, 493-501.	6.3	25
38	Hypoglycemia and Counterregulation in Insulin-Dependent Diabetic Patients: A Comparison of Continuous Subcutaneous Insulin Infusion and Conventional Insulin Injection Therapy. Diabetes Care, 1986, 9, 221-227.	8.6	22
39	Blood Glucose and Glycated Haemoglobin Measurement in Hospital: Which Method?. Diabetic Medicine, 1993, 10, 402-411.	2.3	19
40	Banting Memorial Lecture 2014 Technology and diabetes care: appropriate and personalized. Diabetic Medicine, 2015, 32, 3-13.	2.3	18
41	The Pump Life: Patient Responses and Clinical and Technological Problems. Diabetes, 1985, 34, 37-41.	0.6	17
42	Patterns of Hyperinsulinaemia in Type 1 Diabetic Patients With and Without Nephropathy. Diabetic Medicine, 1989, 6, 685-691.	2.3	17
43	Sensing metabolites using donorâ€“acceptor nanodistributions in fluorescence resonance energy transfer. Applied Physics Letters, 2001, 78, 2796-2798.	3.3	15
44	Insulin Pumps. Diabetes Technology and Therapeutics, 2014, 16, S-17-S-22.	4.4	10
45	The Prospective Association Between Inflammation and Depressive Symptoms in Type 2 Diabetes Stratified by Sex. Diabetes Care, 2019, 42, 1865-1872.	8.6	9
46	A modelling study of the budget impact of improved glycaemic control in adults with Type 1 diabetes in the <scp>UK</scp>. Diabetic Medicine, 2019, 36, 988-994.	2.3	8
47	Sampling and sensing blood glucose. Lancet, The, 1993, 342, 1068.	13.7	6
48	Insulin Pumps. Diabetes Technology and Therapeutics, 2013, 15, S-24-S-28.	4.4	4
49	Improving the Patient Experience With Longer Wear Infusion Sets Symposium Report. Journal of Diabetes Science and Technology, 2022, 16, 775-782.	2.2	3
50	Insulin Pumps. Diabetes Technology and Therapeutics, 2015, 17, S-21-S-26.	4.4	2
51	Insulin Pumps. Diabetes Technology and Therapeutics, 2015, 17, S-21-S-26.	4.4	2
52	Progress towards in vivo glucose sensing with a ferrocene-mediated amperometric enzyme electrode. Hormone and Metabolic Research Supplement Series, 1988, 20, 34-6.	0.2	2
53	Diabetes Technology Meeting 2021. Journal of Diabetes Science and Technology, 2022, , 193229682210902.	2.2	2
54	Diabetes Technology Meeting 2020. Journal of Diabetes Science and Technology, 2021, 15, 916-960.	2.2	1

#	Article	IF	Citations
55	Osmotic and Electrolytic Changes during an Oral Glucose Tolerance Test in Diabetics. Clinical Science and Molecular Medicine, 1978, 54, 23P-23P.	0.8	0
56	Reply from Williamset al.. Diabetic Medicine, 1988, 5, 711-711.	2.3	0